Skip to main content

CASI-Pharmaceuticals-logo

CASI Pharmaceuticals to Raise $25.1 Million in Private Placement of Common Stock and Warrants ROCKVILLE, Md., Sept. 21, 2015 – CASI Pharmaceuticals, Inc. (the “Company”) (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has entered into definitive agreements for a $25.1 million financing led by a China investment fund manager affiliated with the same management team of our current largest shareholder, IDG-Accel China Growth Fund III, L.P.

{iframe}http://www.casipharmaceuticals.com/about-us/news/casi-pharmaceuticals-to-raise-25-1-million-in-private-placement-of-common{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.